Department of Immunology, Chonbuk National University Medical School, Chonju, Chonbuk, Korea.
Immune Netw. 2009 Dec;9(6):209-35. doi: 10.4110/in.2009.9.6.209. Epub 2009 Dec 31.
There has been an explosion of literature focusing on the role of regulatory T (Treg) cells in cancer immunity. It is becoming increasingly clear that Treg cells play an active and significant role in the progression of cancer, and have an important role in suppressing tumor-specific immunity. Thus, there is a clear rationale for developing clinical strategies to diminish their regulatory influences, with the ultimate goal of augmenting antitimor immunity. Therefore, manipulation of Treg cells represent new strategies for cancer treatment. In this Review, I will summarize and review the explosive recent studies demonstrating that Treg cells are increased in patients with malignancies and restoration of antitumor immunity in mice and humans by depletion or reduction of Treg cells. In addition, I will discuss both the prognostic value of Treg cells in tumor progression in tumor-bearing hosts and the rationale for strategies for therapeutic vaccination and immunotherapeutic targeting of Treg cells with drugs and microRNA.
在癌症免疫方面，关于调节性 T (Treg) 细胞作用的文献大量涌现。越来越清楚的是，Treg 细胞在癌症的进展中起着积极和重要的作用，并在抑制肿瘤特异性免疫方面发挥着重要作用。因此，有明确的理由制定临床策略来减少它们的调节影响，最终目标是增强抗肿瘤免疫。因此，Treg 细胞的操纵代表了癌症治疗的新策略。在这篇综述中，我将总结和回顾最近大量的研究，这些研究表明，恶性肿瘤患者的 Treg 细胞增加，通过耗尽或减少 Treg 细胞，在小鼠和人类中恢复抗肿瘤免疫。此外，我还将讨论肿瘤负荷宿主中 Treg 细胞在肿瘤进展中的预后价值，以及用药物和 microRNA 进行治疗性疫苗接种和免疫治疗靶向 Treg 细胞的策略的合理性。
